PDE5i therapy lowers risk of heart failure, death in men with CAD
26 Mar 2021
bởiStephen Padilla
Treatment with phosphodiesterase 5 inhibitor (PDE5i) appears to reduce the risk of death, myocardial infraction (MI), heart failure, and revascularization in men with stable coronary artery disease (CAD) as compared to alprostadil therapy, a study has found.